Factors leading to muscle atrophy and weakness |
|
Disuse |
Associated with weakness, atrophy, changes in fiber type distribution, and metabolic alterations (303–306, 310) |
Inflammation |
Triggering of the muscle proteolysis cascade (102, 116, 322, 325) |
Oxidative stress |
Triggering of the muscle proteolysis cascade (336, 339, 340) |
Associated with reduced muscle endurance (222, 227, 229) |
Protein carbonylation possibly involved in exercise intolerance and weakness (201) |
Hypoxemia |
Decreased muscle protein synthesis |
Activation of muscle degradation through hypoxia-inducible factor/von Hippel–Lindau signaling cascade (347–350) |
Hypercapnia |
Intracellular acidosis/alterations in contractile protein synthesis/degradation (105, 362) |
Low levels of anabolic hormones and growth factors |
Associated with reduced muscle protein synthesis (371, 372) |
Impaired energy balance |
Associated with reduced muscle protein synthesis (381, 383) |
Corticosteroids |
Reduced muscle protein synthesis and enhanced proteolysis through increased myostatin levels and reduced insulin-like growth factor-1 levels (385) |
Vitamin D deficiency |
Associated with muscle weakness, type II atrophy impaired calcium metabolism (392, 400, 405) |
Factors leading to muscle susceptibility to fatigue |
|
Central fatigue—afferent feedback from limb muscles |
Reduced motor output to the contracting muscles (295) |
Reduced O2 delivery (impaired cardiac output, blood flow competition between the respiratory and limb muscle, reduced capillarity) |
Changes in muscle metabolism in favor of glycolysis; accumulation of muscle metabolites associated with muscle fatigue |
Muscle metabolic alteration (reduced oxidative enzyme activity, reduced mitochondrial function) |
Preferential use of glycolysis and accumulation of muscle metabolites associated with muscle fatigue (179, 180, 190, 199, 443) |